Pharmaceutical Research

, Volume 10, Issue 7, pp 970–974

Biodistribution of Micelle-Forming Polymer–Drug Conjugates

Authors

  • Glen S. Kwon
    • International Center for Biomaterials Science, Research Institute for BioscienceScience University of Tokyo
    • Institute of Biomedical EngineeringTokyo Women's Medical College
  • Masayuki Yokoyama
    • International Center for Biomaterials Science, Research Institute for BioscienceScience University of Tokyo
    • Institute of Biomedical EngineeringTokyo Women's Medical College
  • Teruo Okano
    • International Center for Biomaterials Science, Research Institute for BioscienceScience University of Tokyo
    • Institute of Biomedical EngineeringTokyo Women's Medical College
  • Yasuhisa Sakurai
    • International Center for Biomaterials Science, Research Institute for BioscienceScience University of Tokyo
    • Institute of Biomedical EngineeringTokyo Women's Medical College
  • Kazunori Kataoka
    • International Center for Biomaterials Science, Research Institute for BioscienceScience University of Tokyo
    • Department of Materials Science and Technology and Research Institute for BioscienceScience University of Tokyo
Article

DOI: 10.1023/A:1018998203127

Cite this article as:
Kwon, G.S., Yokoyama, M., Okano, T. et al. Pharm Res (1993) 10: 970. doi:10.1023/A:1018998203127
  • 221 Views

Abstract

Polymeric micelles have potential utility as drug carriers. To this end, polymeric micelles based on AB block copolymers of polyethylene oxide (PEG) and poly(aspartic acid) [p(Asp)] with covalently bound Adriamycin (ADR) were prepared. The micelle forming polymer–drug conjugates [PEO-p(Asp(ADR)] were radiolabeled and their biodistribution was investigated after intravenous injection in mice. Long circulation times in blood for some compositions of PEO-p[Asp(ADR)] conjugates were evident, which are usually atypical of colloidal drug carriers. This was attributed to the low interaction of the PEO corona region of the micelles with biocomponents (e.g., proteins, cells). Low uptake of the PEO-p(Asp(ADR)] conjugates in the liver and spleen was determined. The biodistribution of the PEO-p[Asp(ADR)] conjugates was apparently dependent on micelle stability; stable micelles could maintain circulation in blood, while unstable micelles readily formed free polymer chains which rapidly underwent renal excretion. Long circulation times in blood of PEO-p(Asp(ADR)] conjugates are thought to be prerequisite for enhanced uptake at target sites (e.g., tumors).

polymeric micellesdrug delivery systemscancer therapyAdriamycin
Download to read the full article text

Copyright information

© Plenum Publishing Corporation 1993